Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20
CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and CEO, and Timothy S. Pardee, M.D., Ph.D., Co-Chief Medical Officer of the Company, will present at the on Wednesday, Jan. 20.
“As we kick off 2021, we are excited to present the progress that Rafael Pharmaceuticals has made throughout the past year,” said Sanjeev Luther, President and CEO of Rafael. “Cancer metabolism is revolutionizing the way we address hard-to-treat cancers. While we have come far, we also understand that we still have further to go in our fight against rare diseases. I am confident that our team of experts will continue to make significant progress in addressing the remaining challenges of the year ahead.”
Presentation Details:
Date: Wednesday, Jan. 20, 2021
Time: 2:30 p.m. - 3:00 p.m. ET
Location: Virtual
The will be limited to B. Riley Securities Virtual Oncology Investor Conference attendees. An archived replay will be available on the Company's website, .
About CPI-613® (devimistat)
CPI-613® (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. Devimistat is designed to target the mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumor cell multiplication and survival, selectively in cancer cells. Devimistat substantially increases the sensitivity of cancer cells to a diverse range of chemotherapeutic agents. This synergy allows for potential combinations of devimistat with lower doses of these generally toxic drugs to be more effective with lower patient’s side effects. Combination with devimistat represent a diverse range of opportunities to substantially improve patient’s benefit in many different cancers. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal Phase 3 clinical trials in pancreatic cancer (AVENGER 500) and acute myeloid leukemia (ARMADA 2000), and has designated devimistat as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, peripheral T-cell lymphoma and Burkitt’s lymphoma. The EMA has granted orphan drug designation to devimistat for pancreatic cancer and acute myeloid leukemia.
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. The company is developing a new, first-in-class category of metabolic oncology therapeutics that attack hard-to-treat cancers by targeting the metabolic processes the disease needs to survive, grow and proliferate. Rafael Pharmaceuticals’ lead compound, CPI-613® (devimistat), is a highly selective, well-tolerated and effective anti-cancer agent that is being evaluated in ongoing and completed Phase 1, 2 and 3 clinical trials. Devimistat has been granted orphan drug status by the FDA for the treatment of pancreatic cancer, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Burkitt’s,peripheral T-cell lymphomas and soft tissue sarcoma. The Company's investors include Rafael Holdings, Inc. (NYSE AMERICAN: RFL). For more information, please visit.
Safe Harbor Statement
This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
###
Rafael Media Contact:
Vanessa Donohue
(201) 465-8036
